Physician-Led Compounded Tirzepatide for Menopause
Menopausal weight concerns deserve an individualized evaluation of symptoms, body composition, sleep, activity, medications, metabolic health, contraindications, risks, and goals. Highland prescribes compounded tirzepatide, which is not FDA-approved.
Why Tirzepatide's Dual Mechanism Works for Menopausal Weight Gain
Two powerful pathways working together—independent of your reproductive hormones.
Dual-Action Power
Tirzepatide activates both GIP and GLP-1 receptors simultaneously. Tirzepatide acts at both GIP and GLP-1 receptors. Whether it is appropriate during menopause depends on medical history, contraindications, tolerability, access, risks, and goals.
Individualized Monitoring
Approved-product trials do not establish the safety, effectiveness, quality, or expected outcomes of Highland's compounded tirzepatide or predict an individual result.
Zero Estrogen Required
Tirzepatide works through pathways completely independent of estrogen. Your ovaries stopped producing hormones—tirzepatide doesn't care. It functions at full strength regardless of menopausal status.
Why Dual Action Matters During Menopause
Menopause can coincide with changes in body composition, sleep, activity, symptoms, and cardiometabolic risk. The pattern and causes vary, so evaluation considers the full clinical context rather than assuming a fixed metabolic change.
Tirzepatide acts at GIP and GLP-1 receptors. Mechanism alone does not establish candidacy, predict an individual response, or show that a compounded formulation is safer or more effective than an FDA-approved option.
Menopausal status is one part of the clinical evaluation. Highland discusses FDA-approved options first when appropriate; a compounded formulation may be considered only for a documented patient-specific clinical need and is not FDA-approved.
- GIP receptor activity
- GLP-1 receptor activity
- Combined effect: results that vary by patient and cannot be predicted from approved-product trials of brand-name tirzepatide
- Hormone status included in the clinical evaluation
Protecting Muscle During Weight Loss
Menopausal women are already losing muscle mass to aging. The last thing you want is a weight loss approach that accelerates this. That's why we use DEXA body-composition scanning to estimate changes in fat mass and lean mass so nutrition, resistance training, medication, and follow-up can be reassessed.
- DEXA scans track fat vs. muscle changes
- Protein guidance (typically 100+ grams daily)
- Optional peptide therapy for lean mass support
- Focus on sustainable fat loss, not just weight loss
Our goal isn't just a lower number on the scale—it's improved body composition that serves your health for decades to come.
Individualized Menopause Weight Care
Menopause-related weight concerns deserve evaluation without blame or a one-cause explanation. Highland reviews symptoms, medical history, medications, sleep, nutrition, activity, cardiometabolic risk, contraindications, and goals before recommending treatment.
— Dr. Josh Lindsley, DO, DABOM
Tirzepatide for Menopause FAQs
No. Highland discusses FDA-approved options first and limits compounding to documented patient-specific needs. We do not dispense Zepbound or Mounjaro, which are brand-name tirzepatide products manufactured by Eli Lilly and Company. Compounded tirzepatide is prepared by a state-licensed compounding pharmacy under physician supervision. Compounded medications are not FDA-approved.
Menopausal status is one part of the clinical evaluation. Tirzepatide acts at GIP and GLP-1 receptors, but whether treatment is appropriate depends on medical history, contraindications, current medications, tolerability, access, risks, and goals. Highland prescribes compounded tirzepatide, which is not FDA-approved.
A head-to-head trial of FDA-approved products found a greater average reduction in body weight with tirzepatide at 72 weeks in adults with obesity but without diabetes. That trial did not evaluate Highland's compounded formulations and should not predict an individual result. Highland prescribes compounded tirzepatide and compounded semaglutide; we do not dispense brand-name Zepbound, Mounjaro, Wegovy, or Ozempic.
Using tirzepatide and hormone therapy together requires individualized review. The clinician considers route, current medications, contraindications, risks, reproductive considerations, and monitoring needs.
Weight-loss outcomes vary by medication, dose, duration, adherence, health conditions, and patient. Approved-product trials do not establish expected outcomes for a compounded formulation; no amount or timeline is guaranteed. We use DEXA scans to estimate changes in fat mass and lean mass over time. Highland prescribes compounded tirzepatide; those approved-product trials do not establish expected outcomes for a compounded formulation or an individual patient.
Hormone therapy is not a prerequisite for a weight-loss evaluation. Each treatment has separate indications, contraindications, risks, and goals and should be considered through shared decision-making.
Weight loss can include fat mass and lean mass. DEXA may estimate changes in each so nutrition, resistance training, medication, and follow-up can be reassessed; it does not measure muscle directly or guarantee preservation.
Compounded medications are generally not covered by health insurance. Insurance coverage typically applies only to brand-name products such as Zepbound or Mounjaro, which Highland Longevity does not dispense.
Serving Fort Worth & Surrounding Communities
Our clinic is conveniently located in the Fort Worth Alliance area, just minutes from communities throughout the DFW metroplex.
Located at 4801 Golden Triangle Blvd Suite 121, Fort Worth, TX 76244
Ready to Discuss an Individualized Weight-Loss Plan?
Book a free consultation to discuss how compounded tirzepatide's dual mechanism can help you lose weight—even when menopause has changed all the rules. Highland discusses FDA-approved options first and limits compounding to documented patient-specific needs and does not dispense Zepbound or Mounjaro.
Compounded medication disclaimer: Highland discusses FDA-approved options first and limits compounding to documented patient-specific needs. We do not dispense Zepbound®, Mounjaro®, or any other brand-name tirzepatide product manufactured by Eli Lilly and Company.
Compounded tirzepatide is prepared by a state-licensed compounding pharmacy under the supervision of our physician. Compounded medications are not FDA-approved. They are permitted under federal law when an FDA-approved product cannot meet the patient's clinical needs, or when the FDA designates a shortage. Your physician will discuss the implications, risks, and benefits of compounded therapy at your consultation.